Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
New Study: the PCA3 test could be useful to predict the outcome of an initial prostate biopsy
News
- July 28, 2010 - DiagnoCure hires new Chief Financial Officer

- June 9, 2010 - DiagnoCure announces second quarter 2010 results

Events
-
October 3 - 7, 2010
American College of Surgeons 96th Annual Clinical Congress
Washington, D.C., USA
|
1.13
+0.03
|
Open: 1.10 $CAN.
Quotes are delayed.
|


